Faricimab CAS 1607793-29-2

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1607793-29-2

Name

Faricimab

Prop­er­ties

Safe­ty Data

Sym­bol

Sig­nal Word

Warn­ing

WGK Germany

3

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Known Appli­ca­tion

Faricimab is a bis­pe­cif­ic anti­body that is promis­ing for the treat­ment of wet age-relat­ed mac­u­lar degen­er­a­tion (AMD) and dia­bet­ic mac­u­lar ede­ma (DME). It simul­ta­ne­ous­ly tar­gets and blocks two key path­o­gen­ic path­ways – angiopoi­etin-2 (Ang). -2) and vas­cu­lar endothe­lial growth fac­­tor-A (VEGF-A), two path­ways that dri­ve many reti­nal dis­eases that lead to vision loss by desta­bi­liz­ing blood vessels.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Wat­son Bio Lim­it­ed (https://​www​.wat​son​-bio​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.